Sugi Predict

Sugi Predict / Compounds / SCHEMBL1286674

SCHEMBL1286674

SCHEMBL1286674

CC(=O)c1cnn2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.68
▸ RAB9A P51151 8/20 0.68
▸ ALDH1A1 P00352 7/20 0.68
▸ SMN1; SMN2 Q16637 5/20 0.68
▸ MAPT P10636 2/20 0.68
▸ GAA P10253 1/20 0.68
▸ HPGD P15428 1/20 0.68
▸ KDM4E B2RXH2 5/20 0.64
▸ TP53 P04637 2/20 0.64
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ KLF5 Q13887 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ EPHB3 P54753 5/20 0.55
▸ RIPK2 O43353 1/20 0.55
▸ LCK P06239 1/20 0.55
▸ HTT P42858 3/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416200 0.84 EPHB3 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL1044120 0.82 EPHB3 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL30152645 0.82 EPHB3 (0.55) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL11300658 0.82 EPHB3 (0.55) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL19119427 0.82 EPHB3 (0.55) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL1863799 0.81 NPC1 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL6121120 0.81 NPC1 (0.63) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL17321386 0.81 ALDH1A1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL10834334 0.81 NPC1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL25562789 0.81 NPC1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 — — EP claimed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 — — WO claimed
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 — — US disclosed
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-05-29 — — US disclosed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 — — WO disclosed
EP-4183783-A1 IMMUNOMODULATOR Hitgen Inc. (CN) 2023-05-24 — — EP disclosed
EP-4177249-A1 IMMUNOMODULATOR Hitgen Inc. (CN) 2023-05-10 — — EP disclosed
WO-2023076218-A1 SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-05-04 — — WO disclosed
EP-3402790-B1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2021-10-06 — — EP disclosed
US-10065956-B2 Ethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2018-09-04 — — US disclosed
EP-3271353-A1 3-(4-ETHYNYLPHENYL)HEXAHYDROPYRIMIDIN-2,4-DIONE DERIVATIVES AS MODULATORS OF MGLUR4 F. Hoffmann-La Roche AG (CH) 2018-01-24 — — EP disclosed
WO-2006077424-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077428-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077425-A1 COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 — — WO disclosed
EP-0368343-B1 AMELIORATING COMPOSITION FOR DYSMNESIA KYORIN SEIYAKU KABUSHIKI KAISHA (JP) 1993-06-30 — — EP disclosed
US-4097483-A HYPOTENSIVE AND ANTISPASMODIC AGENT KYORIN PHARMACEUTICAL CO., LTD. (JA) 1978-06-27 — — US disclosed
US-4028370-A SMOOTH MUSCLE RELAXANTS, CEREBRAL AND CORONARY DILATORS, HYPOTENSIVE AGENTS KYORIN PHARMACEUTICAL CO., LTD. (JA) 1977-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 NPC1 3526/4885RAB9A 1335/4885ALDH1A1 865/4885
US-10065956-B2 Ethynyl derivatives MC5R, MC4R, MC2R NPC1 807/4885RAB9A 381/4885ALDH1A1 118/4885
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 NPC1 3526/4885RAB9A 1335/4885ALDH1A1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.